Michael Kotsanis

Mr Kotsanis brings 35 years operational leadership experience in global pharmaceutical markets, leading regional franchises at Hospira/Mayne Pharma (oncology injectables, US$500M plus EMEA revenue) and Synthon (generics/biologics), driving commercialisation, licensing and market expansion. He returned to Australia in 2014 to assume the CEO position at Acrux (ASX:ACR), directing pipeline development, business development, capital management/investor relations, and ASX/ASIC compliance for a topical pharmaceutical product developer. Throughout his career he has held Executive Director appointments on the main Board of Synthon (private) and operating subsidiaries of the listed companies. Michael is a Non-Executive Director at ICE Pharma, a private equity owned, Italian pharmaceutical company that manufactures pharmaceutical ingredients. He was formerly a Non-Executive Director at IDT Australia (ASX:IDT) where he was also Chair of the Human Capital/Remuneration Committee and an Audit/Risk Committee member.